Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Xencor, Inc. (XNCR) traded up 1.31% on Friday, hitting $20.04. The stock had a trading volume of 203,466 shares. The company has a 50-day moving average price of $22.65 and a 200 day moving average price of $22.36. The firm’s market cap is $940.40 million. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. Equities analysts forecast that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “John S. Stafford III Buys 24,653 Shares of Xencor, Inc. (XNCR) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/27/john-s-stafford-iii-buys-24653-shares-of-xencor-inc-xncr-stock.html.

A number of research analysts have issued reports on the company. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday. Canaccord Genuity set a $36.00 price objective on Xencor and gave the company a “buy” rating in a research note on Monday. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.00.

Institutional investors have recently bought and sold shares of the company. Emory University acquired a new stake in shares of Xencor in the 2nd quarter worth $1,491,000. State of Wisconsin Investment Board acquired a new stake in shares of Xencor in the 2nd quarter worth $612,000. Goldman Sachs Group Inc. boosted its position in shares of Xencor by 50.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,439 shares of the biopharmaceutical company’s stock worth $6,277,000 after purchasing an additional 87,599 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Xencor by 10.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 219,458 shares of the biopharmaceutical company’s stock worth $5,250,000 after purchasing an additional 19,921 shares in the last quarter. Finally, TD Asset Management Inc. boosted its position in shares of Xencor by 9.3% in the 2nd quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock worth $1,726,000 after purchasing an additional 6,963 shares in the last quarter. 76.85% of the stock is owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.